The AG-120 is the only inhibitor that successfully cleared phase III trials and is an accepted drug candidate for Cholangiocarcinoma, Leukemia, Acute Myeloid Cancer, and solid tumors; however, IDH-305 failed in phase III and the further developmental process is ongoing in IDH-305 modification. Here, IDH1 is linked to cholangiocarcinoma.